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Abstract 
Objectives:   
To evaluate OR costs associated with the two available morcellators in the United States 
in a matched cohort and to determine BPH surgeon’s morcellator preference.   
Materials and methods:   
Patients from 2013, the last year our institution exclusively used the VersaCut™ device 
were matched 1:1 with the most recent patient cohort, utilizing the Wolf Piranha 
morcellator. Cost of morcellation including the expense of OR time and disposable 
instrument costs was calculated. A survey to the Endourological Society email listserv 
was sent to determine morcellator preference. 
Results:   
We identified 142 patients  who underwent HoLEP in 2013.  When compared with the 
VersaCut™group, morcellation efficiency (4.4 versus 7.0 g/min, p<0.01) and expense of 
OR time  ($1420.80 versus $992.21, p<0.005) both favored the Piranha morcellator 
system even when the costs of disposable instruments were factored in to the analysis 
($1338.81versus $1637.50, p<0.05).   
A total of 126 urologist responded to the survey. Of these, 56 (44.5%) perform 
transurethral prostate enucleations, which included 48 (86%) holmium.   More 
endourologists use the VersaCutTM (n= 33, 59%) than the Piranha (n=24, 43%) 
morecellator.  Qualities that impacted the preference of morcellator included: the 
preferred device is safer, faster, easier to use, reusable, and less expensive.    
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Conclusion:  
 We identified a significant improved efficiency and improved cost savings utilizing the 
Piranha morcellator even when controlling for disposable costs. Of the endourologists 
that responded to the survey less than half perform transurethral enucleation.  
Morcellator preference is largely based on safety, efficiency, and ease of use, while cost 
and reusablility were of lesser importance.   
 
Introduction 
Holmium laser enucleation of the prostate (HoLEP) has superior outcomes than 
traditional transurethral resection and has steadily increased in popularity since 
its introduction almost twenty years ago.1-4  HoLEP represents a versatile, well 
investigated surgery for benign prostatic hyperplasia (BPH), with virtually any 
size prostate amenable to treatment, including those prostates previously 
unsuccessfully treated by other modalities.4 5  
HoLEP involves two procedures: enucleation and morcellation.  Although much 
of the previous literature surrounding HoLEP addresses efficiency of enucleation, 
morcellation also plays a vital role in overall procedural time.6  While initial 
investigation noted inefficient morcellation,1 the rates of morcellation have 
improved; however, there are limited options with morcellation devices.  Currently 
there are only two available models in the United States market: the Richard Wolf 
Piranha and the Lumenis VersaCutTM.  The VersCutTM has a reciprocating 
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mechanism, which extends from the tip of the blade with a guillotine action to 
morcellate tissue, whereas the Piranha oscillates from side to side with a 
serrated blade and has a curved unexposed tip to prevent from inadvertent 
bladder injury. 
A randomized trial reported by El Tayeb et al demonstrated comparable 
morcellation rates between the two devices with cost favoring the Lumenis 
device.7  The finding of comparable rates between the two devices is at odds 
with prior in vitro studies and a recent in vivo investigation.8 9 Furthermore, in the 
original study by El Tayeb et al. OR time and overall cost was not explored.  With 
the recent availability of a second morcellation device in the United States we 
sought to determine the current preference of morcellator, as well as a more 
complete picture of cost and morcellation efficiency between the two devices.  
Materials and Methods 
An institutional review board approved prospectively maintained database 
of HoLEP patients was utilized for this study.  We evaluated all patients from 
2013, the last year our institution exclusively used the VersaCut™ morcellator 
with reusable blades and matched them with the most recent patient cohort 
utilizing exclusively the Piranha morcellator with disposable blades.  Patient 
demographics including age, renal function, pre-operative PSA, transrectal 
ultrasound (TRUS) volume, enucleation time, weight of morcellated tissue and 
morcellation time were recorded.  Morcellation time was defined as the time from 
the start of tissue morcellation, indicated by the surgeon, until all tissue has been 
removed.  This includes any time for troubleshooting the morcellator during use.  
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For the cost comparison, morcellation times were compared and multiplied by the 
institutional rate for OR time on a per minute basis specifically for the HoLEP 
procedure.  Blade costs were calculated assuming three uses for the VersaCutTM 
morcellator blade ($216.7 USD) and a single use for the Piranha ($346.6 USD).   
An online survey was sent to endourologists via the Endourological 
Society email listserv.  Data collected included number of years in practice, 
number of enucleations performed annually, morcellator used, and morcellator 
preference. Qualities of a morcellator that impacted preference were also 
assessed on 1-5 Likert scale with 1 being least important and 5 being most 
important.    
Statistical analysis utilizing student t-Test was performed evaluating 
differences in means regarding morcellation efficiency, cost of morcellation 
including the expense of OR time and disposable instrument costs. Fisher’s 
exact was utilized for categorical data analysis.  All analyses were performed 
using JMP®, Version 12.0. (SAS Institute Inc., Cary, NC, 1989-2007), using two-
tailed testing with a significance level of 0.05.  
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Results 
We identified 142 patients within our institutional database that underwent 
HoLEP in 2013 with the VersaCut™ device and compared them to our most 
recent group of patients undergoing the same procedure with the Piranha from 
June 2015 to June 2016.  There were 3 surgeons who performed the procedure 
during this time with fellows participating in the procedure.  A single surgeon (JL) 
performed 233 of the procedures during this timeframe.  There were no 
significant differences between the previous and most recent group with regards 
to patient age, pre-operative prostate specific antigen (PSA), renal function or 
pre-operative prostate volume.(Table 1)   
Intraoperative variables are presented in Table 2.  There was one identified small 
mucosal injury with the VersaCut; however, the injury did not result in prolonged 
catheter drainage, and no injuries were identified with the Piranha morcellator.  
The amount of tissue enucleated was similar between the two groups 72.8 grams 
vs. 77.7 grams, p=0.46. We noted significant improvements in morcellation 
efficiency (4.4 versus 7.0 g/min, p<0.01) and OR time expense ($1420.80 versus 
$992.21, p<0.005) both favoring the Pirahna morcellator system. When the costs 
of disposable instruments were factored into the OR time cost analysis, total 
expense still favored the Piranha morcellator ($1338.81versus $1637.50, 
p<0.05).    
Out of the greater than 2000 active members of the Endourological Society 126 
endourologist responded to the survey. Of these, 56 (44.5%) perform 
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transurethral prostate enucleations, which included: 48 (86%) holmium, 
8(14%)thulium, 4 (7%) bipolar, 2 (4%) photo, 2 (4%) plasma, 1 (2%) protouch 
laser, and 1(2%) diode. For morcellation, more endourologists use the 
VersaCutTM (n= 33, 59%) than the Piranha (n=24, 43%). Other methods of 
morcellation were used by 6 urologists including 4 who use a Storz 
Resectoscope.  When assessing preference, more preferred the Wolf (n=29, 
52%) compared to the Lumenis (n=23, 41%) and 44 (79%) use the morcellator 
they prefer. Reasons for not using the preferred device were the cost of 
operating the device (18%) or cost to acquire the device (3%). Of those who use 
the VersaCutTM, 27% prefer the Piranha; while of those who use the Wolf, zero 
prefer the VersaCutTM  (Figure 1). Qualities that impacted the preferences of one 
morcellator over another, in order of most to least importance were: the preferred 
device is safer, faster, easier to use, reusable, and less expensive (Figure 2).  
There were no differences in responses amongst groups aside from the selection 
of a faster device by more experienced surgeons (p<0.02).  
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Comment 
In a cost analysis between the two currently available morcellators we found the 
Piranha morcellator to be more efficient, reducing OR morcellation times and 
cost, even when controlling for the expense of a disposable instrument.  
Enucleated tissue weight, patient age and use of 5 alpha reductase inhibitors 
were similar between the two groups.  Our findings differ from previous report of 
similar morcellation times between the two devices, which may be a reflection of 
the improved familiarity and ability to troubleshoot the Wolf Piranha system that 
comes with continued use.7  We note that while the VersaCut morcellator blades 
were calculated assuming 3 uses as was noted by El Tayeb and colleagues, it is 
feasible to decrease the expenses by using morcellation blades greater than 
three times.  However, as the blades are reused for large prostates, as in this 
series, they dull.  This dulling effect decreases morcellation efficiency and 
wouldlikely increase operative time.   
We also noted that in a survey of endourologists, of those that responded, less 
than half perform transurethral prostate enucleation.  The preferred morcellator 
for the highest volume surgeons was divided equally between the Lumenis and 
Wolf morcellators.  Furthermore, morcellator safety was the highest concern, 
while cost was the least concern to the surgeon.  While the response rate was 
low, this was a similar rate to a recent survey based study by Becker et al, 
investigating oral anticoagulation and transurethral treatment of benign prostatic 
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obstruction.10 To our knowledge this is the first survey investigation into 
morcellator preference in the endourology community.  
Much of the literature surrounding HoLEP and efficiency is focused on the 
enucleation portion of the procedure as it is the more technically challenging 
aspect and can be influenced by surgical skill.  Dusing et al found that 
enucleation efficiency continues to improve over time with surgeon experience 
increasing to over 1gm/min of tissue enucleation.6  Morcellation remains an 
equally important aspect of the surgery; however, there is little skill associated 
with morcellation and the procedure is highly equipment dependent.  There is 
potential to significantly improve overall OR efficiency if an effective morcellation 
device is employed.   
In a recent randomized clinical trial comparing the two devices El Tayeb et al 
noted that the Piranha morcellator achieved a slightly higher rate of morcellation 
5.6 vs 4.8, this was not significant when compared to the VersaCutTM (p=0.14).7  
The efficiency of morcellation does differ significantly with our current 
investigation as we noted a 7 gm/min morcellation efficiency with the Piranha 
compared to 4.4gm/min with the VersaCut.  Our excellent morcellation efficiency 
noted with the Piranha most likely reflects an improved understanding of the 
equipment and ability to troubleshooting the device as the number of cases with 
the Piranha has increased at our institution. For example, we note that 
decreasing the oscillation rate of the Piranha to 1000/min greatly reduces 
difficulties morcellating dense round “beach ball” tissue.  In the investigation by El 
Tayeb et al, the authors noted a significant cost benefit with the VersaCutTM 
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device ($241 versus $471, p<0.001).  It should be noted that the El Tayeb 
investigation did not calculate OR time into total cost, only that of disposable 
instruments, which favors the VersaCutTM due to reusable blades.  When 
including OR time into the analysis we identified a savings of nearly $300 per 
case.    
In another study comparing reusable blades between the two morcellator 
devices, Elshal et al noted a similarly increased morcellation efficiency with the 
Piranha morcellator at a rate of 6.2 gm/min compared with 2.1 gm/min with the 
VersaCutTM (p=0.00).9  Laser scoring of the adenoma and use of a crown loop for 
extraction of non-morcellated tissue was likewise higher with the VersaCutTM 
group.  Notably, 9% of the cohort had a bladder mucosal injury with the 
VersaCutTM morcellator (p=0.01).  While we noted only a single clinically 
insignificant mucosal injury with the VersaCut and a much higher rate of 
morcellation with the VersaCutTM compared to Elshal’s study, our findings 
favoring the Piranha are similar.   
 
Our investigation is not without limitations, which include the retrospective nature 
of this study increasing recall bias.  However, all data was originally collected in a 
prospective manner using a maintained database.   While OR room costs were 
calculated on a per minute basis and reusable morcellation blades calculated 
based on a maximum of 3 uses per blade, it is possible to increase the number of 
blade uses but likely at the cost of efficiency and thus, an increase in OR time.  It 
is also possible to accumulate more costs for the procedure if multiple blades are 
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utilized during a longer procedure regardless of morcellating system, but again 
this was not measured.  We also note the participation of residents and fellows in 
all aspects of the cases, thus creating a heterogenous group with differing levels 
of morcellation experience in both cohorts.  Finally, our survey response rate was 
low which can create a response bias regarding the preference of morcellator.   
   
Conclusion 
In a matched cohort comparing morcellation cost utilizing both the VersaCut™ 
and Piranha morcellation devices, we identified a significant increase in 
morcellation efficiency.  The increase in morcellation efficiency resulted in shorter 
OR times and an overall cost savings utilizing the Piranha morcellator.  The cost 
savings persisted even when controlling for disposable expenses associated with 
the Piranha device. Of the endourologists that responded to the survey less than 
half perform transurethral enucleation.  Of those, the majority are using their 
preferred device.   Morcellator preference is largely based on safety, efficiency, 
and ease of use, while cost and reusablility were of lesser importance 
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Figure 1.  Current morcellator use versus preferred morcellator 
Figure 2.  Rationale for Morcellator Preference stratified by surgeon volume 
 
Supplementary Figures 
Figure 1. Lumenis VersaCut 
Figure 2. Richard Wolf Piranha 
Figure 3. Morcellation with Richard Wolf Piranha 
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Table 1. Pre-operative demographics 
 2013 (n=142) 2015-2016 (n=142) p-value 
Mean Age (Years) 69.8  69.7 0.92 
Mean Pre-op PSA 
(ng/ml) SD 
9.0 (9.9) 7.1 (7.0) 0.09 
Pre-op Cr  1.2 (0.5) 1.1 (0.4) 0.63 
Trus Volume, mls 
(SD) 
104.4 (50.1) 107.2 (66.9) 0.71 
Use of 5-ARIs  (%) 40.1 44.7 0.47 
ARI-Alpha Reductase Inhibitor 
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Table 2. Intra-operative findings and costs 
 2013 (n=142) Recent (n=142) p-value 
Morcellation Time, min 
(SD) 
20.1 (18.6) 14.0 (16.8) 0.005 
Specimen Weight, gm 
(SD) 
72.8 (48.6) 77.7 (57.6) 0.46 
Morcellation Efficiency, 
gm/min (SD) 
4.4 (2.4) 7.0 (3.0) <0.0001 
Mean Morcellation Cost, 
USD (SD) 
1420.80 
(1313.52) 
992.21 (1185.12) 0.005 
Mean Morcellation costs 
including disposables, 
USD (SD) 
1637.50 
(1313.52) 
1338.81 
(1185.12) 
0.048 
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Figure 1. 
 
 
 
Figure 2. 
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